论文部分内容阅读
目的探讨分析胃癌腹膜转移癌患者进行细胞减灭术(CRS)加腹腔热灌注化疗(HIPEC)的治疗效果。方法选取110例胃癌腹膜癌患者,根据治疗方法均分为CRS组与CRS+HPEC组(n=55)。CRS+HIPEC使用药物羟基喜素碱20 mg+丝裂霉素30 mg,或使用多西他赛120 mg+顺铂120 mg加入生理盐水进行热灌注,持续60~90 min。比较2组生存率。结果 2组患者平均随访期(24±1.5)个月,CRS+HIPEC组患者1年生存率和2年生存率显著高于CRS组,且平均生存期更长,2组对比差异有统计学意义(P<0.05)。2组3年生存率差异无统计意义。结论使用细胞减灭术加腹腔热灌注化疗治疗胃癌腹膜转移癌患者,可延长患者生存期,提高患者生存质量。
Objective To investigate the therapeutic effects of cytoreductive surgery (CRS) plus intraperitoneal hyperthermic perfusion chemotherapy (HIPEC) in gastric cancer patients with peritoneal metastatic carcinoma. Methods One hundred and ten patients with peritoneal carcinoma of the stomach were selected and divided into CRS group and CRS+HPEC group according to treatment methods (n=55). CRS+HIPEC was treated with hydroxycamptothecin 20 mg or mitomycin 30 mg, or docetaxel 120 mg plus cisplatin 120 mg was added into physiological saline for hot perfusion for 60-90 min. Compare two groups of survival rates. Results The average follow-up period of the two groups was (24±1.5) months. The 1-year survival rate and 2-year survival rate in the CRS+HIPEC group were significantly higher than those in the CRS group, and the average survival time was longer. The difference between the two groups was statistically significant. (P<0.05). The difference in 3-year survival rate between the two groups was not statistically significant. Conclusion The use of cytoreductive surgery and intraperitoneal hyperthermic perfusion chemotherapy for the treatment of gastric cancer patients with peritoneal metastasis can prolong survival and improve the quality of life.